Literature DB >> 29931113

Live Vaccination Generates Both Disease Tolerance and Host Resistance During Chronic Pulmonary Infection With Highly Virulent Francisella tularensis SchuS4.

Alicia M Soucy1, Gregory J Hurteau1, Dennis W Metzger1.   

Abstract

Disease tolerance can preserve host homeostasis and limit the negative impact of infections. We report that vaccinated mice survived pulmonary challenge with the extremely virulent SchuS4 strain of Francisella tularensis for at least 100 days, despite the persistence of large numbers (~104) of organisms. Transfer of 100 of these resident bacteria to naive animals caused 100% lethality, demonstrating that virulence was maintained. Tissue damage in the lung was limited over the course of infection and was associated with increased levels of amphiregulin. Mice depleted of CD4+ cells had reduced amphiregulin and succumbed to infection. In addition, neutralization of interferon-γ or depletion of CD8+ cells resulted in increased pathogen loads, bacteremia, and death of the host. Conversely, depletion of Ly6G+ neutrophils had no effect on survival and actually resulted in reduced bacterial levels. Understanding the interplay between host resistance and disease tolerance will provide new insights into the understanding of chronic infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29931113      PMCID: PMC6195663          DOI: 10.1093/infdis/jiy379

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

Review 1.  Immunology of tuberculosis.

Authors:  J L Flynn; J Chan
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity.

Authors:  C M Bosio; K L Elkins
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

3.  Neutrophils exacerbate tuberculosis infection in genetically susceptible mice.

Authors:  Vladimir Yeremeev; Irina Linge; Tatiana Kondratieva; Alexander Apt
Journal:  Tuberculosis (Edinb)       Date:  2015-04-09       Impact factor: 3.131

Review 4.  Disease tolerance: concept and mechanisms.

Authors:  J L McCarville; J S Ayres
Journal:  Curr Opin Immunol       Date:  2017-12-15       Impact factor: 7.486

Review 5.  Subversion of host recognition and defense systems by Francisella spp.

Authors:  Crystal L Jones; Brooke A Napier; Timothy R Sampson; Anna C Llewellyn; Max R Schroeder; David S Weiss
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

6.  Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.

Authors:  Michael Green; Glyn Choules; Debbie Rogers; Richard W Titball
Journal:  Vaccine       Date:  2005-04-08       Impact factor: 3.641

7.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.

Authors:  J Wayne Conlan; Hua Shen; Rhonda Kuolee; Xigeng Zhao; Wangxue Chen
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

8.  Burkholderia mallei cellular interactions in a respiratory cell model.

Authors:  Gregory C Whitlock; Gustavo A Valbuena; Vsevolod L Popov; Barbara M Judy; D Mark Estes; Alfredo G Torres
Journal:  J Med Microbiol       Date:  2009-05       Impact factor: 2.472

9.  IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection.

Authors:  Lydia M Roberts; John S Davies; Gregory D Sempowski; Jeffrey A Frelinger
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

10.  Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection.

Authors:  Bisweswar Nandi; Samuel M Behar
Journal:  J Exp Med       Date:  2011-10-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.